A variety of antiarrhythmic drugs have been used to terminate atrial fibrillation (AF) and to maintain sinus rhythm after spontaneous or electrical cardioversion.' Antiarrhythmic drug therapy to produce and maintain sinus rhythm is fraught with a variety of problems, including incomplete efficacy,2 proarrhythmic properties,3-S and possibly an increased mortality rate. 67 Since some of the more dangerous proarrhythmic potential of antiarrhythmic drugs appears to be related to sodium channel blocking properties,8-10 there has been increased interest in class III drugs, which act by increasing action potential duration (APD) without blocking sodium channels.
Sotalol, an agent with combined class II and class III properties,1',12 has been used both to terminate arrhythmia13 and prevent its occurrence1415 among patients with AF. We have found that d,l-sotalol is capable of terminating AF and preventing its reinduction in an experimental dog model of AF but that reverse usedependent actions on atrial refractoriness appear to limit efficacy of the drug. 16 Since the latter experiments were conducted in dogs whose 3-adrenergic receptors were blocked with nadolol, presumably only the class III effects of sotalol were manifest. Rensma et al17 showed that similar doses of d-sotalol prevent the induction of nonsustained AF in conscious dogs. To our knowledge, these are the only published studies of class III drug action in experimental atrial fibrillation. Ambasilide is a relatively new class III agent'8 that acts by blocking both the rapid and slow components of delayed rectifier current (IK) in guinea pig ventricular myocytes.'9 It thus differs from many other class III drugs such as sotalol, dofetilide, and E-4031, which act selectively on the rapid component (IKr). 20 The molecular structures of ambasilide and d-sotalol are shown in Fig 1. The purpose of the present experiments was to evaluate the efficacy of ambasilide in a canine model of AF previously developed in our laboratory '6,21 
Sterile Pericarditis Model
A total of 6 dogs with sterile pericarditis were studied. Baseline electrophysiological data were obtained as described above for the vagotonic model. AF induction was then attempted with burst atrial pacing (10 to 20 Hz, four times threshold) a total of 10 times, and the duration of AF induced on each occasion was noted. Ambasilide was then administered as described above, and electrophysiological variables and AF inducibility were reassessed during the maintenance infusion as under control conditions. Ambasilide infusion was then stopped, and AF induction was reattempted. When the inducibility of AF returned to baseline values, or after 2 hours (whichever was shorter), low-dose d-sotalol was given and measurements repeated during the maintenance dose. The higher dose of d-sotalol was then given, and measurements were once more repeated.
In two dogs, sustained atrial fibrillation (.30 minutes) was induced under control conditions. Ambasilide was given after AF had been sustained for over 30 minutes. In one of these dogs, sustained AF could once more be induced after ambasilide washout, and the response of AF in this dog to the lower dose of d-sotalol was observed. (Table) in all 12 dogs studied (100% efficacy) and was much more effective than an equal dose of d-sotalol, which terminated AF in 1 of 8 dogs (12.5%, P=.001 versus ambasilide). The addition of a second dose of d-sotalol (8 mg/kg cumulative dose) resulted in AF termination in 7 of 8 dogs (87.5%). The mean plasma concentration of d-sotalol at the time of AF termination was substantially higher for dogs receiving both doses than the concentration of ambasilide required to terminate AF. Plasma concentrations of ambasilide and d-sotalol were kept relatively stable by the maintenance drug infusions (Fig 2) . During the maintenance infusion, sustained (>30 seconds) AF could be induced in the presence of low-dose d-sotalol in all 8 dogs but in only 2 of 12 dogs (17%) receiving ambasilide (P=.002). Effects on Conduction, Refractoriness, and Wavelength
Data Analysis
To assess potential mechanisms determining drug efficacy, effects on atrial effective refractory period (AERP), conduction velocity (CV), and wavelength were established as a function of atrial basic cycle length (BCL). In the absence of vagal stimulation (Fig 3) , both ambasilide and d-sotalol significantly prolonged AERP. The degree of prolongation of AERP by d-sotalol was determined by BCL, with substantially smaller effects noted as BCL decreased. In contrast, the actions of ambasilide on AERP were not significantly altered as BCL was reduced. Similar findings were noted for drug effects on atrial refractoriness in the presence of vagal stimulation (Fig 4) ; however, while effects of ambasilide were better preserved than those of sotalol at short cycle lengths, statistically significant rate-dependent effects of ambasilide were noted. As (Fig 9, top) . On the other hand, ambasilide significantly attenuated the bradycardic response to vagal stimulation (Fig 9, bottom) , indicating antivagal actions. Antivagal actions were unlikely to have been involved in the effects of ambasilide studied during maintenance infusions (eg, effects on AF inducibility, conduction, wavelength, and refractoriness, as shown in Figs 3 Table ) because the vagal stimulation frequency was adjusted during the maintenance drug infusion to produce the same bradycardic effect as under control conditions. On the other hand, vagal stimulation frequency to maintain AF in the first 7 dogs receiving ambasilide was not altered before drug administration. The antivagal actions of the drug could, therefore, have contributed to AF termination in these animals. To determine the efficacy of ambasilide independent of antivagal effects, we used an approach previously applied to evaluate the actions of procainamide.'6 An additional group of 5 dogs was studied in which vagal stimulation frequency was approximately tripled during the production of AF immediately before drug administration. As a result, the bradycardic effect of vagal stimulation in the presence of ambasilide at the frequency used to induce AF immediately before giving the drug was similar to the bradycardic effect under control conditions of the vagal frequency used to produce control AF (Fig 10) . Despite an equieffective level of vagal stimulation in the presence of ambasilide, the drug terminated AF in all 5 dogs, an efficacy significantly greater than that of the same dose of d-sotalol (P=.02; see Table) . Effects on Activation During AF Both d-sotalol and ambasilide slowed atrial activation during AF (Fig 11) . The increase in the mean atrial cycle length produced by 2 Chronic Pericarditis Model Under control conditions, AF was induced during each attempt at induction in all dogs and lasted for an average of 187±90 seconds (range, 6 seconds to 36 minutes).
Ambasilide (mean concentration, 5.0±0.5 mg/L) prevented AF induction in all dogs. In the presence of the drug, no AF could be induced in 4 dogs, and in 2 dogs 1 of 10 induction attempts produced AF that lasted for 20 seconds in 1 dog and 16 seconds in the other (mean AF duration during 10 inductions before drug averaged 407±189 and 329±112 seconds in the same dogs, respectively). In the 2 dogs with sustained AF 230 minutes, ambasilide terminated AF in both cases, after 7.5 minutes in one dog and 3.5 minutes in the other, at plasma concentrations averaging 8.9±1.5 mg/L.
After drug washout (mean ambasilide concentration, 1 (Fig 7) . The latter are similar to control values in the absence of vagal stimulation (Fig 6) , when sustained AF cannot be induced, and are substantially longer than the critical wavelengths needed for AF induction in conscious dogs.17 Both d-sotalol and ambasilide increased the cycle length during vagotonic AF, enlarged reentry circuits, and reduced their number, leading to termination of reentry. These effects on atrial activation during AF can all be explained by increases in AERP and wavelength. Increases in AERP cause a prolongation in the cycle length of functional, "leading circle" reentry,28 as demonstrated to occur in isolated heart models.29 Similarly, increases in wavelength are expected to increase the size of individual circuits and thereby reduce the number of simultaneous reentry circuits that are possible.17 When the number of simultaneous circuits decreases beyond a critical value, AF is unlikely to sustain itself and termination occurs. 30, 31 In the present study, we found that the actions of d-sotalol on AERP show reverse use dependence, similar to our previous observations regarding d,lsotalol. 16, 26 Ambasilide is a new class III drug, which has not previously been evaluated for efficacy against AF. Although at long cycle lengths, the effects of ambasilide on AERP were less than or equal to those of high-dose d-sotalol (Figs 3, 4, and 12) , the drug showed less reverse use dependence of action and produced larger relative increases than d-sotalol at short cycle lengths. This finding may explain the larger increases in AF cycle length produced by ambasilide (Fig 11) , since the AF cycle length is determined by the AERP at the rapid rates of AF. 16, 32 Larger increases in AERP during AF by ambasilide probably contributed to the greater effectiveness of ambasilide than equal doses of d-sotalol in terminating AF.
Potential Implications of Our Findings
We have previously shown that the effectiveness of antiarrhythmic drugs in experimental AF is related to the changes in wavelength for reentry that they produce at rapid activation rates.162126 Reverse use-dependent actions on AERP reduce the ability of d,l-sotalol to increase wavelength as rate increases, and appear to limit the ability of the drug to terminate experimental AF.1626 Flecainide and propafenone increase AERP with positive use dependence, an action that appears to be important to their efficacy in experimental AF.1621 However, their sodium channel blocking actions are associated with an undesirable risk of serious proarrhythmic reactions. Positive use-dependent APD prolongation without sodium channel blockade would seem to be an ideal profile of antiarrhythmic drug action. 33, 34 Ambasilide is considered a class III antiarrhythmic drug,19 a classification consistent with the significant increases in AERP and VERP and lack of change in atrial conduction velocity that we observed in the present experiments. Our results indicate that class III agents may exhibit different patterns of frequencydependent action on atrial refractoriness. Unlike d-sotalol, the effects of ambasilide on both AERP and VERP did not show significant reverse use dependence in the absence of vagal nerve stimulation (Figs 3, 8 , and 12). We were unable to locate published studies of the effects of ambasilide on atrial action potentials, but Takanaka et a118 showed that ventricular action prolongation by ambasilide was independent of stimulation frequency.
Amiodarone has recently been found to produce use-independent prolongation of human ventricular monophasic action potentials. 35 at increased rates because of incomplete interpulse deactivation38 and may therefore contribute to ratedependent action potential abbreviation. The absence of reverse use dependence of actions by amiodarone on human ventricular repolarization35 and the lesser frequency dependence of effects of ambasilide on AERP and VERP compared with sotalol in the present study may be due to an inhibition of Iy,-induced action potential abbreviation at rapid rates. While ambasilide blocks Iy,, it also appears to inhibit IKr to a significant extent. 19 The development of pure IKS blockers may be a useful approach to the introduction of novel class III agents with a more desirable profile of rate-dependent action on atrial refractoriness.
The present study is the first to evaluate the effects of pure class III drugs in animal models of sustained AF. It indicates the significance of the actions of these drugs on atrial refractoriness at rapid rates and the potential importance of rate-dependent AERP changes in governing drug efficacy in AF. Reverse use dependence could render a drug ineffective in terminating AF, but the drug might still be able to prevent AF recurrence at the slow rate of sinus rhythm. A recent clinical study44 showed that sotalol is relatively ineffective in terminating AF but effective in maintaining sinus rhythm after electrical cardioversion, confirming these expectations. Our data suggest that ambasilide might be more effective than d-or d,l-sotalol in terminating clinical AF. This possibility would be interesting to assess in prospective clinical trials. Our study is also the first to analyze class III drug action on activation of the fibrillating atrium and shows that the mechanism of AF termination by class III drugs is consistent with observed changes in AERP and wavelength and with current concepts of functional reentry mechanisms.28,29
Potential Limitations
We measured changes in atrial and ventricular refractoriness. While the latter are closely related to action potential duration and neither sotalol nor ambasilide significantly altered conduction velocity to suggest sodium channel blockade, we cannot be sure that changes in refractoriness result directly and solely from corresponding changes in action potential duration. Furthermore, changes in repolarization of ventricular muscle may not parallel those in the His-Purkinje system, which appears to be the primary target for drug-induced arrhythmogenic early afterdepolarizations. 41 Although we adjusted vagal stimulation frequency to compensate for antivagal actions of ambasilide, we cannot be sure of the quantitative precision of the correction because changes in sinus rate were used to adjust vagal tone, and vagal effects on the atrium may not exactly parallel those on the sinus node. Furthermore, some of the effects of sotalol and ambasilide on vagotonic AF could be due to inhibition of IKACh, an action that might be relatively much less important in nonvagal AF. We therefore evaluated the actions of the drugs in a model of AF (sterile pericarditis) in which vagal tone is not enhanced. In the latter model, ambasilide was uniformly effective and low-dose sotalol ineffective in preventing AF induction, results that are qualitatively very similar to those in the vagotonic model. One limitation of our studies in dogs with pericarditis is that sotalol was studied in the presence of low concentrations of ambasilide rather than in a separate series of animals. On the other hand, the presence of ambasilide should have, if anything, enhanced the efficacy of d-sotalol, so that any bias should have been to overestimate the effectiveness of d-sotalol in terminating AF or preventing its induction.
A final comment relates to the applicability of our results to atrial arrhythmias in general. Since the actions of d-sotalol are quite rate dependent, the drug could be more effective in terminating atrial reentry with slower intrinsic rates than AF 
